Early-stage volume losses in the corpus callosum and thalamus predict the progression of brain atrophy in patients with multiple sclerosis.
Humans
Multiple Sclerosis
/ diagnostic imaging
Corpus Callosum
/ diagnostic imaging
Retrospective Studies
Magnetic Resonance Imaging
/ methods
Brain
/ diagnostic imaging
Multiple Sclerosis, Relapsing-Remitting
/ diagnostic imaging
Central Nervous System Diseases
Atrophy
/ etiology
Thalamus
/ diagnostic imaging
Neurodegenerative Diseases
/ pathology
Brain atrophy
Cluster analysis
FreeSurfer
MRI
Multiple sclerosis
Volumetric analysis
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 02 2024
15 02 2024
Historique:
received:
29
11
2023
revised:
20
12
2023
accepted:
28
12
2023
medline:
11
2
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
ppublish
Résumé
A method that can be used in the early stage of multiple sclerosis (MS) to predict the progression of brain volume loss (BVL) has not been fully established. To develop a method of predicting progressive BVL in patients with MS (pwMS), eighty-two consecutive Japanese pwMS-with either relapsing-remitting MS (86%) or secondary progressive MS (14%)-and 41 healthy controls were included in this longitudinal retrospective analysis over an observational period of approximately 3.5 years. Using a hierarchical cluster analysis with multivariate imaging data obtained by FreeSurfer analysis, we classified the pwMS into clusters. At baseline and follow-up, pwMS were cross-sectionally classified into three major clusters (Clusters 1, 2, and 3) in ascending order by disability and BVL. Among the patients included in Cluster 1 at baseline, approximately one-third of patients (12/52) transitioned into Cluster 2 at follow-up. The volumes of the corpus callosum, the thalamus, and the whole brain excluding the ventricles were significantly decreased in the transition group compared with the nontransition group and were found to be the most important predictors of transition. Decreased volumes of the corpus callosum and thalamus in the relatively early stage of MS may predict the development of BVL.
Sections du résumé
BACKGROUND
A method that can be used in the early stage of multiple sclerosis (MS) to predict the progression of brain volume loss (BVL) has not been fully established.
METHODS
To develop a method of predicting progressive BVL in patients with MS (pwMS), eighty-two consecutive Japanese pwMS-with either relapsing-remitting MS (86%) or secondary progressive MS (14%)-and 41 healthy controls were included in this longitudinal retrospective analysis over an observational period of approximately 3.5 years. Using a hierarchical cluster analysis with multivariate imaging data obtained by FreeSurfer analysis, we classified the pwMS into clusters.
RESULTS
At baseline and follow-up, pwMS were cross-sectionally classified into three major clusters (Clusters 1, 2, and 3) in ascending order by disability and BVL. Among the patients included in Cluster 1 at baseline, approximately one-third of patients (12/52) transitioned into Cluster 2 at follow-up. The volumes of the corpus callosum, the thalamus, and the whole brain excluding the ventricles were significantly decreased in the transition group compared with the nontransition group and were found to be the most important predictors of transition.
CONCLUSION
Decreased volumes of the corpus callosum and thalamus in the relatively early stage of MS may predict the development of BVL.
Identifiants
pubmed: 38171046
pii: S0165-5728(23)00266-7
doi: 10.1016/j.jneuroim.2023.578280
pii:
doi:
Types de publication
Observational Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
578280Informations de copyright
Copyright © 2024 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest IN is serving on scientific advisory boards for Biogen Japan and Novartis Pharma and is receiving honouraria for speaking engagements with Biogen Japan, Mitsubishi Tanabe Pharma, Novartis Pharma, Takeda Pharmaceutical, and Eisai. JF have no conflicts of interest to disclose.